Second-line systemic therapy for the treatment of metastatic renal cell cancer

Medicine and Dentistry

• Cancer Cell 100%
• Systemic Therapy 100%
• Tyrosine-Kinase Inhibitor 100%
• Vasculotropin 66%
• Clear Cell Renal Cell Carcinoma 66%
• Bevacizumab 33%
• Kidney Metastasis 33%
• Temsirolimus 33%
• Mammalian Target of Rapamycin 33%
• Sunitinib 33%
• Pazopanib 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Protein Tyrosine Kinase Inhibitor 100%
• Renal Cell Carcinoma 66%
• Vasculotropin 66%
• Mammalian Target of Rapamycin Inhibitor 33%
• Pazopanib 33%
• Sunitinib 33%
• Kidney Metastasis 33%
• Temsirolimus 33%